Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000032:analysis*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin